RxDoctor Payments Data

Andrew Clothier, DPM

Podiatrist · Searcy, ARNPI 1649667817

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,916 of the $2,259 with a category attached, or 84.9%. 21 manufacturers reported payments, led by Stryker at 38.4% of the total.

$2,259in general payments, 2019–2025

Across 73 payments — averaging $30.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$867
  • Smith+Nephew$196
  • Paratek Pharmaceuticals, Inc.$195
  • AbbVie$190
  • KCI USA, Inc.$105
  • Organogenesis Inc.$82
  • plus $622 from 15 others

What the payments were for

  • Travel & lodging$34215%
  • Food & beverage$1,91685%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,259 in reported general payments places this provider in the 70th percentile of 35 podiatrist providers in Arkansas.

See all podiatrist providers in Arkansas

Medicare billing

Part B allowed, 2024
$131,590
Medicare patients
435
Services billed
1,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuzyraOmadacycline Tosylate32$254,743
Ciclopirox37$1,085
Gentamicin Sulfate16$687
Mupirocin38$251
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen19$182
Cephalexin51$158
Clindamycin Hcl15$118
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$100
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Paratek Pharmaceuticals, Inc.Nuzyra$195$254,74332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 35 podiatrist providers in Arkansas.

Other podiatrist in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →